

6 Literaturverzeichnis

- Aiken RD. Quality of life issues in patients with malignant gliomas. *Semin Oncol* 21; 1994: 273.
- Ammirati M, Galicich JH, Arbit E. Reoperation in the treatment of recurrent intracranial malignant gliomas. *Neurosurgery* 21; 1987: 607.
- An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. *Cell Death Differ* 5 (12); 1998: 1062-1075.
- Andersen AP. Postoperative irradiation of glioblastomas. results in a randomized series. *Acta Radiol Oncol Radiat Phys Biol* 17; 1978: 475.
- Anglade P, Vyas S, Javoy F, Herrero MT, Michel PP, Marquez J, Mouatt Prigent A, Ruberg M, Hirsch EC, Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. *Histol Histopathol* 12; 1997: 25-31.
- Antonsson B, Martinou JC. the Bcl-2 protein family. *Exp Cell Res* 256; 2000: 50-57.
- Aravind L, Dixit VM, Koonin EV. Apoptotic molecular machinery: vastly increased complexity in vertebrates revealed by genome comparisons. *Science* 291; 2001: 1279-1284.
- Aronen HJ, Glass J, Pardo FS. Echo-planar MR cerebral blood volume mapping of gliomas. Clinical utility. *Acta Radiol* 36; 1995: 520.
- Ashkenazi H, Dixit M. Death receptors: signaling and modulation. *Science* 281; 1998: 1305-1308.
- Awad I, Bay JW, Rogers L. Leptomeningeal metastasis from supratentorial malignant gliomas. *Neurosurgery* 19; 1996: 247.
- Baker DM, Jones JA, Nguyen-Van-Tam JS, Lloyd JH, Morris DL, Bourke JB, Steele RJ, Hardcastle JD. Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. *Br J Surg* 81 (7); 1994: 1054-1056.
- Barker FGn, Chang SM, Valk PE. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. *Cancer* 79; 1997: 115.
- Barnard RO, Geddes JF. The incidence of multifocal cerebral gliomas. A histologic study of large hemisphere sections. *Cancer* 60; 1987: 1519.
- Batchelor T, De Angelis LM. Medical management of cerebral metastasis. *Neurosurg Clin N Am* 7; 1996: 435.
- Beauchesne P, Soler C, Mosnier JF. Diffuse vertebral body metastasis from a glioblastoma multiforme: a technetium-99m Sestamibi single-photon emission computerized tomography study. *J Neurosurg* 93 (5); 2000: 887-890.
- Beaulaton J, Lockshin RA. The relation of programmed cell death to development and reproduction: comparative studies and an attempt at classification. *Int Rev Cytol* 79; 1982: 215-235.

Bedrosian I, Sofia RD, Wolff SM, Dinarello CA. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. *Cytokine* 3 (6); 1991: 568-575.

Berger MS. Malignant astrocytomas: surgical aspects. *Semin Oncol* 21; 1994: 172.

Berger MS, Leibel SA, Brunner JM (1996). Primary central nervous system tumors of the supratentorial compartment. *Cancer in the nervous system*. V Levin. New York, Churchill Livingstone.

Biersack HJ, Coenen HH, Stocklin G, Reichmann K, Bockisch A, Oehr P, Kashab M, Rollmann O. Imaging of brain tumors with L-3-[123I]iodo-alpha-methyl tyrosine and SPECT. *J Nucl Med* 30 (1); 1989: 110-112.

Bittar RG, Olivier A, Sadikot AF. Presurgical motor and somatosensory cortex mapping with functional magnetic resonance imaging and positron emission tomography. *J Neurosurg* 91; 1999: 915.

Black P. Brain tumors. *N Engl J Med* 324; 1991: 1471.

Blommaert EFC, Luiken JJFP, Meijer AJ. Autophagic proteolysis: control and specificity. *Histochem J* 29; 1997: 365-385.

Boiardi A. PCV chemotherapy for recurrent glioblastoma multiforme. *Neurology* 56 (12); 2001: 1782.

Borner C, Monney L. Apoptosis without caspases: an inefficient molecular guillotine. *Cell death and differentiation* 6; 1999: 497-507.

Bowman EJ, Siebers A, Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. *Proc Natl Acad Sci U S A* 85 (21); 1988: 7972-7976.

Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. *Ann Oncol* 12 (2); 2001: 259-266.

Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. *Anal Biochem* 72; 1976: 248-254.

Bragg DG, Osborn AG. CNS imaging of neoplasms. *Int J Radiat Oncol Biol Phys* 21; 1991: 841.

Brandes AA, Ermani M, Basso U, Amista P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. *Ann Oncol* 12 (2); 2001: 255-257.

Brandes AA, Ermani M, Basso U, Paris MK, Lumachi F, Berti F, Amista P, Gardiman M, Iuzzolino P, Turazzi S, Monfardini S. Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. *Oncology* 63 (1); 2002: 38-41.

Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amista P, Rotilio A, Licata C, Fiorentino MV. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. *J Clin Oncol* 17 (2); 1999: 645-650.

Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amista P, Nicolardi L, Sotti G, Ermani M. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or

- progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). *J Clin Oncol* 22 (23); 2004: 4779-4786.
- Braumann C, Ordemann J, Wildbrett P, Jacobi CA. Influence of intraperitoneal and systemic application of taurolidine and taurolidine/heparin during laparoscopy on intraperitoneal and subcutaneous tumour growth in rats. *Clin Exp Metastasis* 18 (7); 2000: 547-552.
- Brearley S, George RH. The rate of antimicrobial action of noxythiolin and taurolin. *J Hosp Infect* 1 (3); 1980: 201-209.
- Browne MK. The treatment of peritonitis by an antiseptic - taurolin. *Pharmatherapeutica* 2 (8); 1981: 517-522.
- Browne MK, Leslie GB, Pfirrmann RW. Taurolin: A new chemotherapeutic agent. *Journal of Applied Bacteriology* 41; 1976: 363-368.
- Bursch W, al. e. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. *Carcinogenesis* 17; 1996: 1595-1607.
- Bursch W, Ellinger A, Gerner C, Fröhwein U, Schulte-Hermann R. Programmed cell death (PCD): apoptosis, autophagic PCD or others? *Ann NY Acad Sci* 926; 2000a: 1-12.
- Bursch W, Hochegger K, Torok L, Marian B, Ellinger A, Hermann RS. Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. *J cell Sci* 113; 2000b: 1189-1198.
- Bursch W, Hochegger K, Török L, Marian B, Ellinger A, Schulte-Hermann R. Different fates of cytoskeletal filaments during autophagic and apoptotic types of programmed cell death in mammary carcinoma cells (MCF-7) and colon carcinoma cells (HT29H11). *J Cell Sci* 113; 2000c: 1189-1198.
- Burtscher IM, Skagerberg G, Geijer B. Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. *Am J Neuroradiol* 21; 2000: 84.
- Byrne TN. Imaging of gliomas. *Semin Oncol* 21; 1994: 161.
- Calabresi P, Goulette FA, Darnowski JW. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. *Cancer Res* 61 (18); 2001: 6816-6821.
- Carvalho P, Schwartz RB, Alexander E. Detection of recurrent gliomas with quantitative thallium-201/technetium-99 HMPAO single photon emission computed tomography. *J Neurosurg* 77; 1992: 565.
- Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztain S, Lippa C, Nixon RA. Gene expression and cellular content of cathepsin D in Alzheimer's Disease brain: evidence for early up-regulation of the endosomal-lysosomal system. *Neuron* 14; 1995: 671-680.
- Cecconi F. *Cell* 94; 1998: 727.
- Chai J. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. *Nature* 406; 2000: 855-862.
- Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. *Neurology* 38; 1988: 1371.

- Chang CH, Horton J, Schoenfeld D. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. *Cancer* 52; 1983: 997-1002.
- Chang SM, Kuhn J, Rizzo J. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American brain tumor consortium report. *J Clin Oncol* 16; 1998: 2188-2194.
- Chautan M, Chazal, Cecconi F, Gruss P, Golstein P. Interdigital cell death can occur through a necrotic and caspase independent pathway. *Curr Biol* 9; 1999: 967-970.
- Cheng SY, Su Huang HJ, Nagane M, Ji XD, Wang D, Shih CCY, Arap W, Huang CM, Cavenee WK. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. *Proc Natl Acad Sci U S A* 93; 1996: 8502-8507.
- Cheruku R, Tapazoglou E, Ensley J. The incidence and significance of thromboembolic complications in patients with high grade gliomas. *Cancer* 68; 1991: 2621.
- Chi S, al. e. Oncogenic Ras triggers cell suicide through the activation of a caspase independent cell death program in human cancer cells. *Oncogene* 18; 1999: 2281-2290.
- Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. *J Clin Oncol* 19 (9); 2001: 2449-2455.
- Choucair AK, Levin VA, Gutin PH. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. *J Neurosurg* 22; 1986: 465.
- Chung S, Gumienny TL, Hengartner MO, Driscoli M. A common set of engulfment genes mediates removal of both apoptotic and necrotic cell corpses in *C.elegans*. *Nature Cell Biol* 2; 2000: 931-937.
- Coffey RJ, Lunsford LD, Taylor FH. Survival after stereotactic biopsy of malignant gliomas. *Neurosurgery* 22; 1988: 465.
- Conlan AA, Abramor E, Delikaris P, Hurwitz SS. Taurolidine instillation as therapy for empyema thoracis. A prospective study of 50 patients. *S Afr Med J* 64 (17); 1983: 653-655.
- Cornillon S, Foa C, Davoust J, Buonavista N, Gross JD, Golstein P. Programmed cell death in *Dictyostelium*. *J Cell Sci* 10; 1994: 2691-2704.
- Da Costa ML, Redmond HP, Bouchier-Hayes DJ. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. *J Surg Res* 101 (2); 2001: 111-119.
- Dalgleisg AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. *Nature* 312; 1984: 763-767.
- Daugas E, al. e. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. *FASEB J* 14; 2000: 729-739.
- Davis DL, Hoel D, Percy C. Is brain cancer mortality increasing in industrial countries? *Ann NY Acad Sci* 609 (791); 1990.
- Davis PC, Hidgins PA, Peterman SB. Diagnosis of cerebral metastases: double-dose delayed CT vs contrast enhanced MR imaging. *Am J Neuroradiol* 12 (293); 1991.

De Flora S, Izzotti A, D'Agostini F, Balansky RM. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related endpoints. *Carcinogenesis* 22; 2001: 999-1013.

Deavaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. *J Neurosurg* 78; 1993: 767.

Deen DF, Chiarodo A, Grimm EA, Fike JR, Israel MA, Kun LE, Levin VA, Marton LJ, Packer RJ, Pegg AE, Rosenblum ML, Suit HD, Walker MD, Wikstrand CJ, Wilson CB, Wong AJ, Yung WKA. Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program, National Cancer Institute. *J Neurooncol* 16 (3); 1993: 243-272.

Deininger MH, Weller M, Streffer J, Meyermann R. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma. *Cancer* 86 (9); 1999: 1832-1839.

Deiss LP, Galinka H, Berissi H, Cohen O, Kimchi A. Cathepsin D protease mediates programmed cell death induced by interferon Gamma, Fas/APO-1 and TNF-alpha. *EMBO J* 15; 1996: 3861-3870.

Denier C, Carpentier AF, Mokhtari K, Delattre JY. [Cerebral glioblastomas and systemic metastases]. *Rev Neurol (Paris)* 157 (12); 2001: 1531-1534.

Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. *Genes Dev* 13; 1999: 239-252.

Dietz R, Burger L, Merkel K, Schimrigk K. Malignant gliomas - glioblastoma multiforme and astrocytoma III-IV with extracranial metastases. Report of two cases. *Acta Neurochir (Wien)* 57 (1-2); 1981: 99-105.

Dinapoli RP, Brown LD, Arusell RM. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-gradeglioma. *J Clin Oncol* 11; 1993: 1316.

Dirks PB, Rutka JT. Current concepts in neuro-oncology: the cell cycle- a review. *Neurosurgery* 40; 1997: 1000-1013.

Dofferhoff AS, Esselink MT, de Vries-Hospers HG, van Zanten A, Bom VJ, Weits J, Vellenga E. The release of endotoxin from antibiotic-treated *Escherichia coli* and the production of tumour necrosis factor by human monocytes. *J Antimicrob Chemother* 31 (3); 1993a: 373-384.

Dofferhoff ASM, Esselink MT, deVries-Hospers HG, Zanten A, Bom VJ, Weits J, Vellenga E. The release of endotoxin from antibiotic-treated *Escherichia coli* and the production of tumor necrosis factor by human monocytes. *J Antimicrobial Chemotherapy* 31; 1993b: 373-384.

Doyle WK, Budinger TF, Valk PE. Differentiation of cerebral radiation necrosis from tumor recurrence by 18F-FDG and 82Rb positron emission tomography. *J Comput Assist Tomogr* 11; 1987: 563.

Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c dependent caspase activation by eliminating IAP inhibition. *Cell* 102; 2000: 33-42.

Duncan CG, Goodman GB, Ludgate CM. The treatment of adult supratentorial high grade astrocytomas. *J Neurooncol* 13; 1992: 63.

Elliott K, Ge K, Du W, Prendergast GC. The c-Myc interacting adaptor protein Bln1 activates a caspase independent cell death program. *Oncogene* 19; 2000: 4669-4684.

EORTC.

- Erb F, Febvay N, Imbenotte M. Structural investigation of a new organic antiseptic: taurolidine. A Spectroscopic study of its stability and equilibria in various solvents. *Talanta* 29; 1982: 953-958.
- Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. *J Immunol* 148 (7); 1992: 2207-2216.
- Fadul C, Wood J, Thaler H. Morbidity and mortality of craniotomy for excision of supratentorial gliomas. *Neurology* 38; 1988: 1374.
- Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001). EORTC QLQ-C30 Scoring Manual. Brüssel, EORTC Data Center.
- Fazeny-Dorner B, Veitl M, Wenzel C, Piribauer M, Rossler K, Dieckmann K, Ungersbock K, Marosi C. Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. *Anticancer Drugs* 14 (6); 2003: 437-442.
- Ferrari G, Yan CY, Greene LA. N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells. *J Neurosci* 15 (4); 1995: 2857-2866.
- Fien HA, Dear KB, Loeffler JS. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. *Cancer* 71; 1993: 2585.
- Fine HA, Dear KBG, Loeffler JS, Black P, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. *Cancer* 71; 1993: 2585-2597.
- Finn JT, al. e. Evidence that Wallerian degeneration and localized axon degeneration induced by local neurotrophin deprivation do not involve caspases. *J Neurosci* 20; 2000: 1333-1341.
- Foghsgaard L. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. *J Cell Biol* 153; 2001: 999-1009.
- Fontana M, Stanton C, Pompili A. Late multifocal gliomas in adolescents previously treated for acute lymphoblastic leucemia. *Cancer* 60; 1987: 1510.
- Frankel SA, German WJ. Glioblastoma multiforme. Review of 219 cases with regard to natural history, pathology, diagnostic methods and treatment. *J Neurosurg* 15; 1958: 489.
- Frei K, Ambar B, Adachi N, Yonekawa Y, Fontana A. Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis. *J Neuroimmunology* 87; 1998: 105-113.
- Frohlich KU, Madeo F. Apoptosis in yeast - a monocellular organism exhibits altruistic behavior. *FEBS Lett* 473; 2000: 6-9.
- Fruehauf JP, Zonis S, al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC. Selective and synergistic activity of L-S, R-buthionine sulfoximine on malignant melanomas is accompanied by decreased expression of glutathione-S-transferase. *Pigment Cell Res* 10 (4); 1997: 236-249.
- Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. *Neurology* 51; 1998a: 1250-1255.
- Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, Shi X, Rao JS, Levin VA, Kyritsis AP. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. *Nat Med* 4; 1998b: 685-690.

- Galanis E, Buckner J. Chemotherapy for high-grade gliomas. *Br J Cancer* 82; 2000: 1371.
- Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. *J Clin Oncol* 23 (23); 2005: 5294-5304.
- Galanis E, Buckner JC, Schomber PJ. Effectice chemotherapy for advanced CNS embryonal tumors in adults. *J Clin Oncol* 15; 1997: 2939-2944.
- Gamis AS, Egelhoff J, Roloson G, Young J, Woods GM, Newman R, Freeman AI. Diffuse bony metastases at presentation in a child with glioblastoma multiforme. A case report. *Cancer* 66 (1); 1990: 180-184.
- Gardiner KR, Anderson NH, McCaigue MD, Erwin PJ, Halliday MI, Rowlands BJ. Enteral and parenteral anti-endotoxin treatment in experimental colitis. *Hepatogastroenterology* 41 (6); 1994: 554-558.
- Gidley MJ, Sanders JK, Myers ER, Allwood MC. The mode of antibacterial action of some 'masked' formaldehyde compounds. *FEBS Lett* 127 (2); 1981: 225-227.
- Glantz MJ, Hofmann JM, Coleman RE. Identification of early recurrence of primary central nervous system tumors by 18F-fluorodeoxyglucose positron emission tomography. *Ann Neurol* 29; 1991: 347.
- Glioma-Meta-analysis-Trialists-Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. *Lancet* 359; 2002: 1011-1017.
- Gonzales DH, Neupert W. Biogenesis of mitochondrial c-type cytochrome. *J Bioenerg Biomembr* 22; 1990: 753-768.
- Gorman SP, McCafferty DF, Woolfson AD, Jones DS. A comparative study of the microbial antiadherence capacities of three antimicrobial agents. *J Clin Pharm Ther* 12 (6); 1987a: 393-399.
- Gorman SP, McCafferty DF, Woolfson AD, Jones DS. Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agent. *J Appl Bacteriol* 62 (4); 1987b: 315-320.
- Gorman SP, McCafferty DF, Woolfson AD, Jones DS. Electron microscope observations of bacterial cell surface effects due to taurolidine treatment. *Lett Appl Microbiol* 4; 1987c: 103-109.
- Gortz G. Local antiseptic and anti-endotoxin measures in intra-abdominal infections. *Langenbecks Arch Chir* 382 (4 Suppl 1); 1997: S37-41.
- Goyal L. Cell death inhibition: keeping caspases in check. *Cell* 104; 2001: 805-808.
- Grant R, Liang BC, Page MA. Age influences chemotherapy response in astrocytomas. *Neurology* 45; 1995: 929.
- Grant R, Naylor B, Junck L, Greenberg HS. Clinical outcome in aggressively treated meningeal gliomatosis. *Neurology* 42; 1992: 252.
- Green DR, Reed JC. Mitochondria and apoptosis. *Science* 281; 1998: 1309-1312.
- Green JA. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. *Cancer Res* 44 (11); 1984: 5427-5431.

Green SB, Byar DP, Walker MD. Comparisons of carmustine procarbazine and high dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. *Cancer Treat Rep* 67; 1983a: 121-127.

Green SB, Byar DP, Walker MD. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. *Cancer Treat Rep* 67; 1983b: 121.

Griffith OW. Mechanism of action, metabolism, and toxicity of buthionin sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. *J Biol Chem* 257 (22); 1982: 13704-13712.

Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by Buthionine Sulfoximine (S-n-Butyl Homocysteine Sulfoximine). *J Biol Chem* 254 (16); 1979: 7558-7560.

Grossman SA, Hochberg FH, Fisher J. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. *Cancer Chemother Pharmacol* 432; 1998: 118-126.

Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. Tumor derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. *Cancer Res* 59; 1999: 1592-1598.

Hakem R. *Cell* 94 (3); 1998: 339.

Hamada Y, Mizoguchi M, Suzuki SO, Iwaki T. Accumulation of class I mutant p53 and apoptosis induced by carboplatin in a human glioma cell line. *Brain Tumor Pathol* 15 (2); 1998: 77-82.

Hamilton RJ, Sweeney PJ, Pelizzari CA. Functional imaging in treatment planning of brain lesions. *Int J Radiat Oncol Biol Phys* 37; 1997: 181.

Harsh GR, Levin VA, Gutin PH. Reoperation for recurrent intracranial malignant gliomas. *Neurosurgery* 21; 1987: 615.

Hasmall SC, Roberts RA. The perturbation of apoptosis and mitosis by drugs and xenobiotics. *Pharmacol Ther* 82 (1); 1999: 63-70.

Hengartner MO. The biochemistry of apoptosis. *Nature* 07; 2000: 770-776.

Hirt UA, Gantner F, Leist M. Phagocytosis of nonapoptotic cells dying by caspase independent mechanisms. *J Immunol* 164; 2000: 6520-6529.

Hochberg FH, Miller DC. Primary central nervous system lymphoma. *J Neurosurg* 68; 1988: 835.

Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. *Neurology* 30; 1980: 907.

Hofmann E (1985). *Funktionelle Biochemie des Menschen*. Berlin, Akademie Verlag.

Holler N, et al. Fas triggers an alternative, caspase 8 independent cell death pathway using the kinase RIP as effector molecule. *Nature Immunology* 1; 2000: 489-495.

Hovenden JL, Phillips G. Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. *Br J Surg* 82 (2); 1995: 280.

Hsu E, Keene D, Ventureyra E, Matzinger MA, Jimenez C, Wang HS, Grimard L. Bone marrow metastasis in astrocytic gliomata. *J Neurooncol* 37 (3); 1998: 285-293.

Iwaki T, Iwaki A, Fukumaki Y, Tateishi J. Alpha B-crystallin in C6 glioma cells supports their survival in elevated extracellular K⁺: the implication of a protective role of alpha B-crystallin accumulation in reactive glia. *Brain Res* 673; 1995: 47-52.

Jäättelä M. Escaping cell death: survival proteins in cancer. *Exp Cell Res* 248; 1999: 30-43.

Jäättelä M, Tschopp J. Caspase-independent cell death in T lymphocytes. *Nature Immunology* 4 (5); 2003: 416-423.

Jäättelä M, Wissing D, Kokholm K, Kalunki T, Egeblad M. Hsp70 exerts its anti apoptotic function downstream of caspase 3 like proteases. *EMBO J* 17; 1998: 6124-6134.

Jacobi CA, Ordemann J, Bohm B, Zieren HU, Sabat R, Muller JM. Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model. *Am J Surg* 174 (3); 1997a: 359-363.

Jacobi CA, Peter FJ, Wenger FA, Ordemann J, Müller JM. New therapeutic strategies to avoid intra- and extraperitoneal metastases during laparoscopy: results of a tumor model in the rat. *Dig Surg* 16; 1999a: 393-399.

Jacobi CA, Sabat R, Ordemann J, Wenger F, Volk HD, Muller JM. Peritoneal instillation of taurolidine and heparin for preventing intraperitoneal tumor growth and trocar metastases in laparoscopic operations in the rat model. *Langenbecks Arch Chir* 382 (4 Suppl 1); 1997b: S31-36.

Jacobi CA, Wildbrett P, Volk T, Müller JM. Influence of different gases and intraperitoneal instillation of antiadherent or cytotoxic agents on peritoneal tumor cell growth and implantation with laparoscopic surgery in a rat model. *Surg Endosc* 13; 1999b: 1021-1025.

Jaeckle KA. Neuroimaging for central nervous system tumors. *Semin Oncol* 18; 1991: 150.

Jänisch W (1988). Pathologie der Geschwülste des Nervensystems. Neuropathologie. Tumoren des Nervensystems. W Jänisch, D Schreiber, H Güthert. München, Urban & Fischer: 336-343.

Janus TJ, Kim EE, Tilbury R. Use of 18F-fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. *Ann Neurol* 33; 1993: 540.

Jelsma R, Bucy PC. The treatment of glioblastoma multiforme of the brain. *J Neurosurg* 27; 1967: 388.

Jeremic B, Shibamoto Y, Grujicic D, Milicic B, Stojanovic M, Nikolic N, Dagovic A, Aleksandrovic J. Combined treatment modality for anaplastic oligodendroglioma: a phase II study. *J Neurooncol* 43 (2); 1999: 179-185.

Jia L, Dourmashkin RR, Allen PD, Gray AB, Newland AC, Kelsey SM. Inhibition of autophagy abrogates tumor necrosis factor alpha induced apoptosis in human T-lymphoblastic leukaemic cells. *Br J Haematol* 98; 1997: 673-685.

Johansson M, Bergenheim AT, Widmark A, Henriksson R. Effects of radiotherapy and estramustine on the microvasculature in malignant glioma. *Br J Cancer* 80 (1-2); 1999: 142-148.

Jolesz FA, Schwartz RB, Gutmann CRG (1993). Diagnostic imaging of gliomas. Astrocytomas: Diagnosis and treatment. PM Black, W Schoene, LA Lampson. Boston, Blackwell Scientific.

Jones DS, Gorman SP, McCafferty DF, Woolfson AD. The effects of three non-antibiotic, antimicrobial agents on the surface hydrophobicity of certain micro-organisms evaluated by different methods. *J Appl Bacteriol* 71 (3); 1991: 218-227.

- Joza N. Essential role of the mitochondrial apoptosis inducing factor in programmed cell death. *Nature* 410; 2001: 549-554.
- Junck L, Strawderman M, Ross DA. Prognostic value of PET-FDG scans in untreated gliomas. *Neurology* 45; 1995: 387.
- Jurewitsch B, Jeejeebhoy KN. Taurolidine lock: the key to prevention of recurrent catheter-related bloodstream infections. *Clin Nutr* 24 (3); 2005: 462-465.
- Jurewitsch B, Lee T, Park J, Jeejeebhoy K. Taurolidine 2% as an antimicrobial lock solution for prevention of recurrent catheter-related bloodstream infections. *JPEN J Parenter Enteral Nutr* 22 (4); 1998: 242-244.
- Kaluza J, Adamek D, Pyrich M. PCNA and protein P53 in recurrent supratentorial glial brain tumors: studies on correlation between morphology and tumor progression. *Pol J Pathol* 46 (3); 1995: 155-161.
- Kaplan AM, Bandy DJ, Manwaring KH. Functional brain mapping using positron emission tomography scanning in preoperative neurosurgical planning for pediatric brain tumors. *J Neurosurg* 91; 1999: 797.
- Kappelle AC, Postma TJ, Taphoorn MJ, Groeneveld GJ, van den Bent MJ, van Groeningen CJ, Zonnenberg BA, Sneeuw KC, Heimans JJ. PCV chemotherapy for recurrent glioblastoma multiforme. *Neurology* 56 (1); 2001: 118-120.
- Karnofsky DA, Burchenal JH (1949). The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of chemotherapeutic agents. CM McLeod. New York, Columbia University Press: 191-205.
- Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueudre C, Del Fiore G, Luxen A, Reznik M. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. *J Nucl Med* 39 (5); 1998: 778-785.
- Kelly PJ, Daumas-Duport C, Scheithauer BW. Stereotactic histologic correlations of computed tomography and magnetic resonance imaging defined abnormalities in patients with glial neoplasms. *Mayo Clin Proc* 62; 1987: 450.
- Kernohan JW, Mabon RF, Svien HJ. A simplified classification of the gliomas. *Proc Staff Meet Mayo Clin* 24; 1949: 71-75.
- Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. *Cancer* 73; 1994: 2013-2026.
- Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. *Brit J Cancer* 26; 1972: 239-257.
- Kim JH, Klionsky DJ. Autophagy, Cytoplasm-to-vacuole targeting pathway, and pexophagy in yeast and mammalian cells. *Ann Rev Biochem* 69; 2000: 303-342.
- Kitanaka C, Kuchino Y. Caspase independent programmed cell death with necrotic morphology. *Cell death and differentiation* 6; 1999: 508-515.
- Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. *Science* 290; 2000: 1717-1721.
- Kluck RM, Bossy-Wetzell E, Green DR, Newmeyer DD. The release of cytochrome C from mitochondria: a primary site for Bcl-2 regulation of apoptosis. *Science* 271; 1997: 1132-1136.

- Knight BI, Skellern GG, Browne MK, Pfirrmann RW. The characterisation and quantitation by high-performance liquid chromatography of the metabolites of taurolin [letter]. *Br J Clin Pharmacol* 12 (3); 1981: 439-440.
- Knight BI, Skellern GG, Smail GA. NMR Studies and GC analysis of the antibacterial agent taurolidine. *Journal of Pharmacological Sciences* 72 (6); 1983a: 705-707.
- Knight BI, Skellern GG, Smail GA, Browne MK, Pfirrmann RW. NMR Studies and GC analysis of the antibacterial agent taurolidine. *J Pharm Sci* 72 (6); 1983b: 705-707.
- Koldehoff M, Zakrzewski JL. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. *Int J Antimicrob Agents* 24 (5); 2004: 491-495.
- Komata T, Kondo Y, Koga S, Ko SC, Chung LW, Kondo S. Combination therapy of malignant glioma cells with 2-5A antisense telomerase RNA and recombinant adenovirus p53. *Gene Ther* 7; 2000: 2971-2079.
- Kondziolka D, Bernstein M, Resch L. Significance of hemorrhage into brain tumors: Clinicopathological study. *J Neurosurg* 67; 1987: 852.
- Koopman G, Reutelingsperger CP, Kuijten GAM, Keehnen RMJ, Pals ST, van Oers MHJ. Annexin V for flow cytometric detection of phosphatidylserine expression of B cells undergoing apoptosis. *Blood* 84; 1994a: 1415-1420.
- Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RMJ, Pals ST, van Oers MHJ. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. *Blood* 84 (5); 1994b: 1415-1420.
- Kornblith PL. The role of cytotoxic chemotherapy in the treatment of malignant brain tumors. *Surg Neurol* 44; 1995: 551-552.
- Kramer RA. Chemosensitization of L-phenylalanine Mustard by the Thiol-modulating Agent Buthionine Sulfoximine. *Cancer Res* 47 (6); 1987: 1593-1597.
- Krammer PH. *Nature* 407 (6805); 2000: 789.
- Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. *J Neurosurg* 78; 1993: 762.
- Kroemer G, Reed JC. Mitochondrial control of cell death. *Nature Med* 6; 2000: 513-519.
- Krummreich C, Holsbach M, Stöcklin G. Direct electrophilic radioiodination of tyrosine analogues: their in vivo stability and brain uptake in mice. *Appl Radiat Isot* 45; 1994: 929-935.
- Kunstle G, al. e. Concanavalin A hepatotoxicity in mice: tumor necrosis factor mediated organ failure independent of caspase 3-like protease activation. *Hepatology* 30; 1999: 1241-1251.
- Laird AD. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. *Cancer Res* 60; 2000: 4152-4160.
- Lampl Y, Eshel Y, Gilad R, Sarova-Pinchas I. Glioblastoma multiforme with bone metastasis and cauda equina syndrome. *J Neurooncol* 8; 1990: 167.
- Landy HJ, Feun L, Schwade JG. Retreatment of intracranial gliomas. *South Med J* 87; 1994: 211.

- Lang FF, Yung WK, Sawaya R, Tofilon PJ. Adenovirus-mediated p53 gene therapy for human gliomas. *Neurosurgery* 45 (5); 1999: 1093-1104.
- Langen KJ, Clauss RP, Holschbach M, Muhlensiepen H, Kiwit JC, Zilles K, Coenen HH, Muller-Gartner HW. Comparison of iodotyrosines and methionine uptake in a rat glioma model. *J Nucl Med* 39 (9); 1998: 1596-1599.
- Langen KJ, Ziemons K, Kiwit JC, Herzog H, Kuwert T, Bock WJ, Stocklin G, Feinendegen LE, Muller-Gartner HW. 3-[¹²³I]iodo-alpha-methyltyrosine and [methyl-¹¹C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. *J Nucl Med* 38 (4); 1997: 517-522.
- Laster SM, Wood JG, Gooding LR. Tumro necrosis factor can induce both apoptotic and necrotic forms of cell lysis. *J Immunol* 141; 1988: 2629-2634.
- Lavoie JN, Nguyen M, Marcellus RC, Branton PE, Shore GC. E4orf4, a novel adenovirus death factor that induces p53 independent apoptosis by a pathway that is not inhibited by zVAD-fmk. *J Cell Biol* 140; 1998: 637-645.
- Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, Berger MS, Chang S. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcome Project. *J Neurosurg* 99 (3); 2003: 467-473.
- Ledson MJ, Cowperthwaite C, Walshaw MJ, Gallagher MJ, Williets T, Hart CA. Nebulised taurolidine and B cepacia bronchiectasis. *Thorax* 55 (1); 2000: 91-92.
- Lee SH, Kim JH, Rhee CH. Loss of heterozygosity on chromosome 10, 13q(Rb), 17p, and p53 gene mutations in human brain gliomas. *J Korean Med Sci* 10; 1995: 442-448.
- Legler JM, Ries LA, Smith MA. Brain and other central nervous system cancers: recent trends in incidence and mortality. *J Natl Cancer Inst* 91; 1999: 1382-1390.
- Lehninger AL, Nelson DL, Cox MM (1993). Principles of Biochemistry. New York, Worth Publishers Inc.
- Leibel SA, Sheline GE (1986). Radiotherapy in the treatment of cerebral astrocytomas. Neuro-Oncology: Primary malignant brain tumors. DG Thomas. Baltimore, Johns Hopkins Univ Press.
- Leist M. Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis. *Exp Cell Res* 249; 1999: 396-403.
- Leist M, Jäättelä M. Four deaths and a funeral: from caspases to alternative mechanisms. *Nature Reviews* 2; 2001: 1-10.
- Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. *J Exp Med* 185; 1997: 1481-1486.
- Leithauser ML, Rob PM, Sack K. Pentoxifylline, cyclosporine A and taurolidine inhibit endotoxin-stimulated tumor necrosis factor-alpha production in rat mesangial cell cultures. *Exp Nephrol* 5 (1); 1997: 100-104.
- Leverrier Y, Ridley AJ. Apoptosis: caspases orchestrate the rock 'n' bleb. *Nature Cell Biol* 3; 2001: E91-E93.

Levin VA, Edwards MS, Wright DC. Modified procarbazine, CCNU, and vincristine (PCV3) combination chemotherapy in the treatment of malignant brain tumors. *Cancer Treat Rep* 64; 1980: 237.

Levin VA, Gutin PH, Leibel S (1993). Neoplasms of the Central Nervous System. *Cancer: Principles and Practice of Oncology*. VT DeVita, S Hellmann, SS Rosenberg. Philadelphia, Lippincott Co.: 1679-1733.

Levin VA, Prados MD. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosurea resistance. *J Clin Oncol* 10; 1992: 766.

Levin VA, Silver P, Hannigan J. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristin (PCV) over BCNU for anaplastic gliomas: NCOG 6G6I final report. *Int J Radiat Oncol Biol Phys* 18; 1990: 321.

Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome C and dATP dependent formation of Apaf-1 (Caspase-9 complex) initiates an apoptotic protease cascade. *Cell* 91; 1997: 479-489.

Linder MM, Ott W, Wesch G. [Antibacterial therapy of purulent peritonitis: a prospective randomized study on the effects of antibiotics and taurolin, a new chemotherapeutic and antiendotoxic agent (author's transl)]. *Chir Forum Exp Klin Forsch*; 1980: 67-71.

Little D, Regan M, Keane RM, Bouchier-Hayes D. Perioperative immune modulation. *Surgery* 114 (1); 1993: 87-91.

Liu SQ, Sajo K, Todoroki T, Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumor sections. *Nat Med* 1; 1995: 267-271.

Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell free extracts: requirement for dATP and Cytochrome C. *Cell* 86; 1996: 147-157.

Lockshin RA, Osborne B, Zakeri Z. Cell death in the third millennium. *Cell death and differentiation* 7; 2000: 2-7.

Lockshin RA, Zakeri Z. Caspase independent cell deaths. *Curr Opin Cell Biol* 14; 2002a: 727-733.

Lockshin RA, Zakeri Z. Caspase independent cell deaths. *Curr Opin Cell Biol* 14; 2002b: 727-733.

Lockshin RA, Zakeri Z. Apoptosis, autophagy, and more. *The International Journal of Biochemistry & Cell Biology* 36; 2004a: 2405-2419.

Lockshin RA, Zakeri Z. Caspase-independent cell death? *Oncogene* 23; 2004b: 2766-2773.

Longee DC, Friedman HS, Albright RE, Jr. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. *J Neurosurg* 72; 1990: 583.

LoRusso PM, Tapazoglou E, Zarbo RJ, Cullis PA, Austin D, Al-Sarraf M. Intracranial astrocytoma with diffuse bone marrow metastasis: a case report and review of the literature. *J Neurooncol* 6 (1); 1988: 53-59.

Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity and apoptotic signal transduction: lessons from knockout mice. *Immunity* 10; 1999: 629-639.

- Louis DN, Gusella JF. A tiger behind many doors: multiple genetic pathways to malignant glioma. *Trends genet* 11; 1995: 412-415.
- MacDonald DR. Response criteria for phase II studies of supratentorial malignant glioma. *J Clin Oncol* 8; 1990: 1277-1280.
- Mak M, Fung L, Strasser JF. Distribution of drugs following controlled delivery to the brain interstitium. *J Neurooncol* 26; 1995: 91-102.
- Mancini M, Nicholson DW, Roy S, Thornberry NA, Peterson EP, Casciola-Rosen LA, Rosen A. The caspase 3 precursor has a cytosolic and mitochondrial distribution: implications for apoptotic signaling. *J Cell Biol* 140; 1998: 1485-1495.
- Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. *J Exp Med* 182 (5); 1995: 1545-1556.
- Mateo V, al. e. CD47 ligation induces caspase independent cell death in chronic lymphocytic leukemia. *Nat Med* 5; 1999: 1277-1284.
- Mathiasen IS, Lademann U, Jäättelä M. Apoptosis induced by Vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. *Cancer Res* 59; 1999: 4848-4856.
- Matsumara H, al. e. Necrotic death pathway in Fas receptor signalling. *J Cell Biol* 151; 2000: 1247-1256.
- Mattson MP. Apoptosis in neurodegenerative disorders. *Nature Rev Mol Cell Biol* 1; 2000: 120-129.
- McCarthy NJ, Whyte MKB, Gilbert CS, Evan GI. Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak. *J Cell Biol* 136; 1997: 215-227.
- McCartney AC, Browne MK (1988a). Clinical studies on administration of taurolidine in severe sepsis: a preliminary study. Bacterial endotoxins: pathophysiological effects, clinical significance and pharmacological control. New York, Alan R. Liss Inc.: 130.
- McCartney AC, Browne MK. Clinical studies on administration of taurolin in severe sepsis: a preliminary study. *Progr Clin Biol Res* 272; 1988b: 361-371.
- McCourt M, Wang JH, Sookhai S, Redmond HP. Taurolidine inhibits tumor cell growth in vitro and in vivo. *Ann Surg Oncol* 7 (9); 2000: 685-691.
- Metzstein MM. Genetics of programmed cell death in *C. elegans*: past, present and future. *Trends Genet* 14 (10); 1998: 410-416.
- Mihara F, Ikeda M, Rothman MI, Numaguchi Y, Kristt D. Vertebral body metastasis of glioblastoma multiforme with epidural mass formation. Contrast-enhanced MRI study. *Clin Imaging* 18 (4); 1994: 386-389.
- Miyashita T, Kitada S, Krajewski S, W.A. H, Delia D, Reed JC. Overexpression of the Bcl-2 protein increases the half-life of p21 Bax. *J Biol Chem* 270; 1995: 26049-26052.
- Moehler H (1995). Influence of taurolidine on blood coagulation. Zurich.

- Monson JR, Donohue JH. Early burn excision and systemic response to endotoxin [letter; comment]. *Surgery* 110 (1); 1991: 119-120.
- Monson JR, Ramsey PS, Donohue JH. Taurolidine inhibits tumour necrosis factor (TNF) toxicity--new evidence of TNF and endotoxin synergy. *Eur J Surg Oncol* 19 (3); 1993: 226-231.
- Monson JRT, Ramsey PS, Donohue JH. Preliminary evidence that taurolidine is anti-neoplastic as well as anti-endotoxin and anti-microbial. *Br J Surg* 77 (8); 1990: A711.
- Murray K, Kun LE, Cox J. Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature. *J Neurosurg* 65; 1986: 600.
- Myers ER, Allwood MC. The interaction between taurolin and endotoxin. *Microbiol Lett* 13; 1980: 141-147.
- Nash T. The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. *Biochem J* 55 (3); 1953: 416-421.
- National-Cancer-Institute (1999). Common toxicity criteria manual, National Cancer Institute.
- Nazzaro JM, Neuwelt EA. The role of surgery in the management of supratentorial intermeditae and high grade astrocytomas in adults. *J Neurosurg* 73; 1990: 331.
- Nelson DF, Diener-West M, Horton J. Combined modality approach to treatment of malignant gliomas - re-evaluation of RTOG7401/ECOG1374 with long term follow up: a joint study of Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group. *NCI Monogr* 6; 1988: 279-284.
- Nelson SJ. Imaging of brain tumors after therapy. *Neuroimaging Clin N Am* 9; 1999: 801.
- Nicotera P, Leist M, Manzo L. Neuronal cell death: a demise with different shapes. *Trends Pharmacol Sci* 20; 1999: 46-51.
- Nitsche D, Hamelmann H (1985). Quantitative Untersuchungen zur Endotoxin-Neutralisation durch Taurolin in vitro und in vivo. Taurolin. Ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektionen. WL Brückner, RW Pfirman. München, Wien, Baltimore, Urban & Schwarzenberg: 64-69.
- Nosseri C. Possible involvement of poly (ADP-ribose)polymerase in triggering stress-induced apoptosis. *Exp Cell Res* 212; 1994: 367-373.
- Nylandsted J, al. e. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor specific death program that is independent of caspases and bypasses Bcl-2. *Proc Natl Acad Sci U S A* 97; 2000: 7871-7876.
- O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P, Stevens MFG. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. *European Journal of Cancer* 29A (7); 1993: 940-942.
- Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N, Mineura K, Uemura K. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. *AJNR Am J Neuroradiol* 17 (2); 1996: 345-353.
- Oguz H, Oguz E, Karadede S. Effect of taurolidine on the normal eyelid and conjunctival flora. *Curr Eye Res* 21 (5); 2000: 851-855.

- Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. *Acta Neuropathol (Berl)* 109 (1); 2005a: 93-108.
- Ohgaki H, Kleihues P. Population based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. *J Neuropathol Exp Neurol* 64 (6); 2005b: 479-489.
- Ohgaki H, Watanabe K, Peraud A, Biernat W, von Deimling A, Yasargil MG, Yonekawa Y, Kleihues P. A case history of glioma progression. *Acta Neuropathol (Berl)* 97 (5); 1999: 525-532.
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Amer J Clin Oncol* 5; 1982: 649-655.
- Paglin S, Hollister T, Delohery T, Hackett N, McMahon M, Sphicas E, Domingo D, Yahalom JA. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. *Cancer Res* 61; 2001: 439-444.
- Pang D, Ashmead JW. Extranural metastasis of cerebellar glioblastoma multiforme. *Neurosurgery* 10 (2); 1982: 252-257.
- Pardo FS, Aronen HJ, Kennedy D. Functional cerebral imaging in the evaluation and radiotherapeutic treatment planning of patients with malignant glioma. *Int J Radiat Oncol Biol Phys* 30; 1994: 663.
- Petersdorf SH, Berger MS (1996). Concepts in neurosurgery: the molecular basis of neurosurgical disease. Molecular Basis of Chemotherapy for Brain Tumors. C Raffel, GR Harsh. Baltimore, Williams & Wilkins: 198-210.
- Petiot A, Ogier-Denis E, Blommaert EFC, Meijer AJ, Codogno P. Distinct classes of phosphatidylinositol 3' kinases are involved in signalling pathways that control macroautophagy in HT29 cells. *J Biol Chem* 275; 2000: 992-998.
- Pfirschmann RW (1985). Taurolin-ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektionen. Taurolin. Ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektionen. WL Brückner, RW Pfirschmann. München, Wien, Baltimore, Urban & Schwarzenberg: 3-23.
- Piepmeyer JM. Observations on the current treatment of low grade astrocytic tumors of the cerebral hemispheres. *J Neurosurg* 67; 1987: 177.
- Plotkin M, Eisenacher J, Bruhn H, Wurm R, Michel R, Stockhammer F, Feussner A, Dudeck O, Wust P, Felix R, Amthauer H. 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study. *J Neurooncol* 70 (1); 2004: 49-58.
- Pollack IF, Claassen D, Al-Shboul Q. Low grade gliomas of the cerebral hemispheres in children: An analysis of 71 cases. *J Neurosurg* 82; 1995: 536.
- Ponten J, Westermark B. Properties of human malignant glioma cells in vitro. *Med Biol* 56 (4); 1978: 184-193.
- Prados MD, Rodriguez L, Chamberlain M. Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine. *Neurosurgery* 24; 1989: 806.
- Prados MD, Scott C, Sandler H, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ, Jr. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404 [see comments]. *Int J Radiat Oncol Biol Phys* 45 (5); 1999: 1109-1115.

- Price AC, Runge VM, Allen JH. Primary glioma: diagnosis with magnetic resonance imaging. *Comput Tomogr* 10; 1985: 325.
- Puri RK. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma. *Toxicol Pathol* 27 (1); 1999: 53-57.
- Qi XM, He H, Zhong H, Distelhorst CW. Baculovirus p35 and Z-VAD-fmk inhibit thapsigargin-induced apoptosis of breast cancer cells. *Oncogene* 15; 1997: 1207-1212.
- Quarello F, Forneris G. Prevention of hemodialysis catheter-related bloodstream infection using an antimicrobial lock. *Blood Purif* 20 (1); 2002: 87-92.
- Quevedo JF, Buckner JC, Schmidt JL. Thromboembolism in patients with high grade glioma. *Mayo Clin Proc* 69; 1994: 329.
- Quigley MR, Maroon JC. The relationship between and the extent of the resection in patients with supratentorial malignant gliomas. *Neurosurgery* 29; 1991: 385.
- Quignon F, al. e. PML induces a novel caspase independent death process. *Nature Genet* 20; 1998: 259-265.
- Radhakrishnan K, Mokri B, Parisi JE, O`Fallon WM, Sunku J, Kurland LT. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. *Ann Neurol* 37; 1995: 67-73.
- Ralff MC. Social controls on cell survival and cell death. *Nature* 356; 1992: 397-400.
- Reding R, Pfirman RW. Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. *Br J Surg* 82 (4); 1995: 569.
- Redmond HP, Leahy AL, Carey JA, Darzi A, Maxwell B, Keane FB, Tanner WA. Beneficial effects of taurolidine in experimental pancreatitis. *J Surg Res* 56 (3); 1994: 256-260.
- Reisser C, Mielenz H, Junemann K. Initial clinical experience with taurolidin instillation into the area of the middle area. *HNO* 42 (10); 1994: 643-646.
- Reith HB. Therapy of peritonitis today. Surgical management and adjuvant therapy strategies. *Langenbecks Arch Chir* 382 (4 Suppl 1); 1997: S14-17.
- Rez G, Palfia Z, Fellinger E. Occurrence and inhibition by cycloheximide of apoptosis in vinblastine-treated murine pancreas. A role for autophagy? *Acta Biol Hung* 42; 1991: 133-140.
- Ribizzi I, Darnowski JW, Goulette FA, Wagner EF, Simms E, Calabresi P (2001a). Taurolidine: a novel agent for bone marrow purging. Annual Meeting of the American Association for Cancer Research.
- Ribizzi I, Han Z, Darnowski JW, Goulette FA, Calabresi P (2001b). Taurolidine: mechanism of action of a novel and safe cytotoxic agent for cancer therapy. Proce Annual Meeting of the American Association for Cancer Research.
- Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Phase II trial of gefitinib in recurrent glioblastoma. *J Clin Oncol* 22 (1); 2004: 133-142.
- Rietschel ET, Hase S, King MT, Redmond J, Lehmann V. Chemical structure of Lipid A. *Microbiology* 42; 1977: 262-268.

Riggs JE. Rising primary malignant brain tumor mortality in the elderly: a manifestation of differential survival. *Arch Neurol* 52; 1995: 571-575.

Roach HI, Clarke NM. Physiological cell death of chondrocytes in vivo is not confined to apoptosis. New observations on the mammalian growth plate. *J Bone Joint Surg* 82; 2000: 601-613.

Roberts LR, Adjei PN, Gores GJ. Cathepsins as effector proteases in hepatocyte apoptosis. *Cell Biochem Biophys* 30; 1999: 71-88.

Robinson JD, Flashner MS. The NaK activated ATPase. Enzymatic and transport properties. *Biochem Biophys Acta* 549 (2); 1979: 145-176.

Rosman C, Westerveld GJ, Kooi K, Bleichrodt RP. Local treatment of generalised peritonitis in rats; effects on bacteria, endotoxin and mortality. *Eur J Surg* 165 (11); 1999: 1072-1079.

Rosman C, Westerveld GJ, van Oeveren W, Kooi K, Bleichrodt RP. Effect of intraperitoneal antimicrobials on the concentration of bacteria, endotoxin, and tumor necrosis factor in abdominal fluid and plasma in rats. *Eur Surg Res* 28 (5); 1996: 351-360.

Roth JG, Elvidge AR. Glioblastoma multiforme. A clinical survey. *J Neurosurg* 17; 1959: 236.

Roy S, Nicholson DW. Cross talk in cell death signaling. *J Exp Med* 192; 2000: F21-F25.

Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. *Ann Neurol* 13; 1983: 334.

Sadik AR, Port R, Garfinkel B, Bravo J. Extracranial metastasis of cerebral glioblastoma multiforme: case report. *Neurosurgery* 15 (4); 1984: 549-551.

Saeki K, Yuo A, Okuma E, Yazaki Y, Susin SA, Kroemer G, Takaku F. Bcl-2 down regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. *Cell death and differentiation* 7; 2000: 1263-1269.

Safgren SL, Reid JM, Buckner JC, Rajkumar SV, Rios R, Ames MM. Pharmacokinetics of dacarbazine and its active metabolites MTIC and HMMTIC in patients with recurrent glioma. *Proc Am Assoc Cancer Res* 39; 1998: 327.

Salcman M. Surgical resection of malignant brain tumors: Who benefits? *Oncology* 2; 1988: 47.

Sandberg-Wollheim M, Malmstrom P, Stromblad LG. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. *Cancer* 68; 1991: 22.

Sandvig K, van Deurs B. Toxin induced cell lysis: protection by 3-methyladenine and cycloheximide. *Exp Cell Res* 200; 1992: 253-262.

Savill J, Fadok VA. Corpse clearance defines the meaning of cell death. *Nature* 407; 2000: 784-788.

Sawaya R, Glas-Greenwalt P. Postoperative venous thromboembolism and brain tumors: Part II. Hemostatic profile. *J Neurooncol* 14; 1992: 127.

Scevola D, Barbarini G, Marone P, Azzini M, Filice C, Bernardi R. [Anti-endotoxin therapy in liver diseases]. *G Ital Chemioter* 26 (1-2); 1979: 241-256.

- Schierle G, al. e. Differential effects of Bcl-2 overexpression on the fibre outgrowth and survival of embryonic dopaminergic neurons in intracerebral transplants. *Eur J Neurosci* 11; 1999: 3073-3081.
- Schlappbach R, Fontana A. Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycine induced apoptosis in glioma cells. *Acta Biochem Biophys* 1359; 1997: 174-180.
- Schmitt CA, Lowe SW. Apoptosis and therapy. *J Pathol* 187; 1999: 127-137.
- Schneider P. *J Exp Med* 187; 1998: 1205.
- Schold SC, Herndon JE, Burger PC. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. *J Clin Oncol* 11; 1993: 77.
- Scholtan W, Schmid J. The binding of penicillins on the proteins of the blood and tissues. *Arzneimittelforschung* 12; 1962: 741-750.
- Schulze-Osthoff K. *Eur J Biochem* 254; 1998: 439.
- Schulze-Osthoff K, al. e. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. *J Biol Chem* 267; 1992: 5317-5323.
- Schwartz LM, Smith SW, Jones MEE, Osborne B. Do all programmed cell deaths occur via apoptosis? *Proc Natl Acad Sci U S A* 90; 1993: 980-984.
- Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG, Forsyth P. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. *Ann Neurol* 46 (2); 1999: 183-188.
- Sebag-Montefiore DJ, Douek E, Kingston JE. Intracranial germ cell tumors. I. Experience with platinum based chemotherapy and implications for curative chemoradiotherapy. *Clin Oncol* 4; 1992: 345-350.
- See SJ, Levin VA, Yung WK, Hess KR, Groves MD. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. *Neuro-oncol* 6 (3); 2004: 253-258.
- Seglen PO, Jordan PB. 3-methyladenine, a specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. *Proc Natl Acad Sci U S A* 79; 1982: 1889-1892.
- Sehgal A. Molecular changes during the genesis of human gliomas. *Semin Surg Oncol* 14; 1998: 3-12.
- Shapiro WR. Therapy of adult malignant brain tumors: What have clinical trials taught us? *Semin Oncol* 13; 1986: 38.
- Shapiro WR, Green SB, Burger PC. Randomised trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. *J Neurosurg* 71; 1989: 1.
- Shapiro WR, Shapiro JR. Biology and treatment of malignant glioma. *Oncology* 12; 1998: 233-240.
- Shen L, Dean NM, Glazer RI. Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Calpha antisense oligonucleotide. *Mol Pharmacol* 55 (2); 1999: 396-402.
- Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. *Mol Cell Neurosci* 9; 2002: 459-470.

- Shinoura N, Yoshida Y, Asai A, Kirino T, Hamada H. Relative level of expression of Bax and Bcl-XL determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax. *Oncogene* 18 (41); 1999: 5703-5713.
- Sihn YS, Guillory JK, Kirsch LE. Quantitation of taurolidine decomposition in polymer solutions by chromotropic acid formaldehyde assay method. *J Pharm Biomed Anal* 16 (4); 1997a: 643-650.
- Sihn YS, Guillory JK, Kirsch LE. Quantitation of taurolidine decomposition in polymer solutions by chromotropic acid formaldehyde assay method. *J Pharm Biomed Anal* 16 (4); 1997b: 643-650.
- Silvani A, Eoli M, Salmaggi A, Lamperti E, Maccagnano E, Broggi G, Boiardi A. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. *J Neurooncol* 66 (1-2); 2004: 203-208.
- Silverman C, Marks JE. Prognostic significance of contrast enhancement in low grade astrocytomas of the adult cerebrum. *Radiology* 139; 1981: 211.
- Simpson JR, Horton J, Scott C. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. *Int J Radiat Oncol Biol Phys* 26; 1993a: 239.
- Simpson JR, Horton J, Scott C. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. *Int J Radiat Oncol Biol Phys* 26; 1993b: 239.
- Slater EC. Application of inhibitors and uncouplers for a study of oxidative phosphorylation. *Meth Enzymol* 10; 1967: 48-57.
- Slee EA, Zhu H, Chow SC, MacFarlane M, Nicholson DW, Cohen GM. Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (z-VAD.fmk) inhibits apoptosis by blocking the processing of CPP32. *Biochem J* 315; 1996: 21-24.
- Soffiatti R, Ruda R, Bradac GB, Schiffer D. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. *Neurosurgery* 43 (5); 1998: 1066-1073.
- Soldani C, Scovassi AI. Poly(ADP-Ribose)polymerase cleavage during apoptosis. an update. *Apoptosis* 7; 2002: 321-328.
- Spector DL, Goldman RD, Leinwand LA (1998). Culture and biochemical analysis of cells. *Cells. A laboratory manual*. New York, Cold Spring Harbor Laboratory Press. 1: 15.13-15.14.
- Srinivasula SM. A conserved XIAP interaction motif in caspase 9 and Smac/DIABLO regulates caspase activity and apoptosis. *Nature* 410; 2001: 112-116.
- Steinbach-Lebbin C, Ganz AJ, Chang A, Waser PG. Pharmacokinetics of Taurolin. *Arzneimittelforschung* 32 (12); 1982: 1542-1546.
- Stendel R, Kubota H, Frei K. Taurolidin and taurultam exert antineoplastic activity via a mixed type of programmed cell death. *J Cancer Res Clin Oncol* 130 (suppl. 1); 2004a: 105-106.
- Stendel R, Kubota H, Frei K, Mohler H. Antineoplastic activity of taurolidine, taurultam and taurultam-glucose. *publication in progress*; 2005.

- Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W, Brock M. Treatment of glioblastoma with intravenous taurolidine. First clinical experience. *Anticancer Res* 24 (2C); 2004b: 1143-1147.
- Stendel R, Scheurer L, Schlatterer K, Bigler L, Stadler U, Fiss I, Mohler H. Pharmacokinetics of Taurolidine and its Metabolites following Repetitive Intravenous Infusion measured using HPLC-MS. *publication in progress*; 2006.
- Stendel R, Scheurer L, Schlatterer K, Gminski R, Mohler H. Taurolidine-Fibrin-Sealant-Matrix using spray application for local treatment of brain tumors. *Anticancer Res* 24 (2B); 2004c: 631-638.
- Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M, Mohler H. Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. *Anticancer Res* 23 (3B); 2003a: 2309-2314.
- Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M, Mohler H. Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. *Anticancer Res* 23 (3B); 2003b: 2309-2314.
- Stendel R, Stoltenburg-Didinger G, Brock M (2001). The aminosulphonic acid derivative taurolidine induces apoptotic changes in brain tumor cells. 12th World Congress of Neurosurgery, Sydney, Australia.
- Stendel R, Stoltenburg-Didinger G, Brock M. Apoptotic changes in brain tumor cells induced by taurolidine. *Journal of Cancer Research and Clinical Oncology* 128 (Suppl. 1); 2002a: 150.
- Stendel R, Stoltenburg-Didinger G, Brock M. Taurolidine - underestimated antineoplastic effect? *J Cancer Res Clin Oncol* 128 (Suppl. 1); 2002b: 140.
- Stendel R, Stoltenburg-Didinger G, Lotte Al-Keikh C, Wattrodt M, Brock M. The effect of taurolidine on brain tumor cells. *Anticancer Res* 22 (2A); 2002c: 809-814.
- Stendel R, Stoltenburg-Didinger G, Lotte Al-Keikh C, Wattrodt M, Brock M. The effect of taurolidine on brain tumor cells. *Anticancer Res* 22 (2A); 2002d: 809-814.
- Strasser A, O`Connor L, Dixit VM. Apoptosis signaling. *Ann Rev Biochem* 69; 2000: 217-245.
- Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. *J Neurosurg* 93 (6); 2000: 1003-1013.
- Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncology* 7 (5); 2006: 359-360.
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Brandes AA, Cairncross JG, Lacombe D, Mirimanoff RO (2004). Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme. Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. ASCO, New Orleans.
- Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. *Curr Neurol Neurosci Rep* 5 (3); 2005: 198-206.
- Stupp R, Weber DC. The role of radio- and chemotherapy in glioblastoma. *Onkologie* 28 (6-7); 2005: 315-317.
- Suda T. *J Exp Med* 186 (12); 1997: 2045.

- Sun D, Liu Q, Liu W, Hu W. Clinical application of 201TI SPECT imaging of brain tumors. *J Nucl Med* 41; 2000: 5.
- Susin SA, Lorenzo HK, Zamzami N, Marzo I, Brenner C, Larochette N, Prevost MC, Alzari PM, Kroemer G. Mitochondrial release of caspase-2 and -9 during the apoptotic process. *J Exp Med* 189; 1999a: 381-394.
- Susin SA, Lorenzo HK, Zamzami N, Marzo I, Show BE, Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderowski DP, Penninger JM, Kroemer G. Molecular characterization of mitochondrial apoptosis inducing factor. *Nature* 397; 1999b: 441-446.
- Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, Daugas E, Geuskens M, Kroemer G. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. *J Exp Med* 184; 1996: 1331-1341.
- Sze G, Milano E, Johnson C. Detection of brain metastasis: comparison of contrast enhanced MR with unenhanced MR and enhanced CT. *Am J Neuroradiol* 11; 1990: 785.
- Tatter SB. Recurrent malignant glioma in adults. *Curr Treat Options Oncol* 3 (6); 2002: 509-524.
- Thiel A, Pietrzyk U, Sturm V. Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration: technical case report. *Neurosurgery* 46; 2000: 232.
- Thoams LLM, Sturk A, Büller HR, Joop K, ten Cate JW (1985). The in vitro inactivation of endotoxins by taurolidine. Taurolin. Ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektionen. WL Brückner, RW Pfirman. München, Wien, Baltimore, Urban & Schwarzenberg: 78-81.
- Thornberry NA, Lazebnik Y. Caspases: enemies within. *Science* 281 (5381); 1998: 1312-1316.
- Traub WH, Leonhard B, Bauer D. Enterococcus faecium: in vitro activity of antimicrobial drugs, singly and combined, with and without defibrinated human blood, against multiple-antibiotic-resistant strains. *Chemotherapy* 39 (4); 1993a: 254-264.
- Traub WH, Leonhard B, Bauer D. Taurolidine: in vitro activity against multiple-antibiotic-resistant, nosocomially significant clinical isolates of Staphylococcus aureus, Enterococcus faecium, and diverse Enterobacteriaceae. *Chemotherapy* 39 (5); 1993b: 322-330.
- Trent S, Kong A, Short SC, Traish D, Ashley S, Dowe A, Hines F, Brada M. Temozolomide as second-line chemotherapy for relapsed gliomas. *J Neurooncol* 57 (3); 2002: 247-251.
- Tyler JL, Diksic M, Villemure JG. Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. *J Nucl Med* 28; 1987: 1123.
- Vanags DM, Porn-Ares MI, Coppola S, Burgess DH, Orrenius S. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. *J Biol Chem* 271; 1996: 31075-31085.
- Vankemmel M, Scherpereel P, Erb F, Sonnenfeld H, Verkindre AM, Brice A (1982). Nouvelle approche fondamentale de la chimiothérapie anti-infectieuse en chirurgie abdominale: l'utilisation par voie locale et générale d'un antiseptique: la taurolidine., Monographie de la Société de Réanimation de Langue Française.
- Vaux DL, Korsmeyer SJ. *Cell* 96 (2); 1999: 245.

- Vercammen D. Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death. *J Exp Med* 188; 1998: 919-930.
- Verhagen AM. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. *Cell* 102; 2000: 43-53.
- Verhoven B, Schlegel RA, Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. *J Exp Med* 182 (5); 1995: 1597-1601.
- Verma V. Ultrastructural changes in human endothelium at different phases of the menstrual cycle and their functional significance. *Gynecol Obstet Invest* 15; 1983: 193-212.
- Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger CP. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. *J Immunol Methods* 184 (1); 1995: 39-51.
- Vertosick FTJ, Selker RG. Brain stem and spinal metastasis of supratentorial glioblastoma multiforme: A clinical series. *Neurosurgery* 27; 1990: 516.
- Vogt C. Untersuchungen über die Entwicklungsgeschichte der Geburtshelferkröte (*Alytes obstetricans*). 1842.
- Volbracht C, Leist M, Kolb SA, Nicotera P. Apoptosis in caspase inhibited neurons. *Mol Med* 7; 2001: 36-48.
- Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. *Acta Neurochir (Wien)* 145 (1); 2003: 5-10.
- Wagenknecht B. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. *Cell death and differentiation* 6; 1999: 370-376.
- Walker MD, Alexander EJ, Hunt WE. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial. *J Neurosurg* 49; 1978: 333.
- Walker MD, Green SB, Byar DP. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. *N Engl J Med* 303; 1980: 1323.
- Walker MD, Hurwitz BS. BCNU 1.3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of malignant brain tumor. A preliminary report. *Cancer Chemother Rep* 54; 1970: 263-271.
- Walker MD, Strike TA, Sheline GE. An analysis of dose effect relationship in the radiotherapy of malignant gliomas. *Int J Radiat Oncol Biol Phys* 5; 1979: 1725.
- Wallner KE, Galicich JH, Krol G. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. *Int J Radiat Oncol Biol Phys* 16; 1989: 1405.
- Walter AW, Hancock ML, Pui CH. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. *J Clin Oncol* 16; 1998: 3761-3767.
- Wang CC, Li J, Teo CS, Lee T. The delivery of BCNU to brain tumors. *J Controlled Release* 61 (1-2); 1999: 21-41.
- Waser PG, Sibling E, Ganz AJ (1985). Pharmakologie und Toxikologie von Taurolidin. Taurolin. Ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektionen. WL Brückner, RW Pfirrmann. München, Wien, Baltimore, Urban und Schwarzenberg: 24-37.

- Waterhouse NJ, al. e. Calpain activation is upstream of caspases in radiation induced apoptosis. *Cell death and differentiation* 5; 1998: 1051-1061.
- Weller M, Schmidt C, Roth W. Chemotherapy of human glioma: prevention of efficacy by dexamethasone? *Neurology* 48; 1997: 1704.
- Werner G, Hagenmaier H, Drautz H, Baumgartner A, Zahner H. Metabolic products of microorganisms. 224. Bafilomycins, a new group of macrolide antibiotics. Production, isolation, chemical structure and biological activity. *J Antibiot (Tokyo)* 37 (2); 1984: 110-117.
- Werner MH, Phuphanich S, Lyman GH. The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. *Cancer* 76; 1995: 1634-1642.
- Westermarck B, Nister M. Molecular genetics of human glioma. *Curr Opin Oncol* 7; 1995: 220-225.
- Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jaaskelainen J, Ram Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. *Neuro Onc* 5 (2); 2003: 79-88.
- Wicki O, Pfirrmann RW (1979). Taurolin bei Peritonitis. Aktuelle Probleme in Chirurgie und Orthopädie. C Burri, A Rüter. München, Zürich, Verlag Hans Huber. 12: 42-48.
- Wiestler OD, Schmidt MC, von Deimling A, Reifenberger G, Deckert-Schluter M, Radner H, Pietsch T, Louis DN. New developments and controversies in the neuropathology of malignant gliomas. Molecular pathways in the formation of gliomas. *Front Radiat Ther Oncol* 33 (3); 1999: 123-138.
- Wilken B, Dechent P, Herms J, Maxton C, Markakis E, Hanefeld F, Frahm J. Quantitative proton magnetic resonance spectroscopy of focal brain lesions. *Pediatr Neurol* 23 (1); 2000: 22-31.
- Willatts SM, Radford S, Leitermann M. Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial. *Crit Care Med* 23 (6); 1995: 1033-1039.
- Willatts SM, Speller DC, Winter RJ. Incidence of gram-negative bacteraemia in sepsis syndrome. Implications for immunotherapy. *Anaesthesia* 49 (9); 1994: 751-754.
- Wilson CB, Bodrey EB, Enot KJ. 1.3-bis-(2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. *Cancer Chemother Rep* 54; 1970: 273-281.
- Winger MJ, MacDonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. *J Neurosurg* 71; 1989a: 487.
- Winger MJ, MacDonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. *J Neurosurg* 71; 1989b: 487.
- Witham TF, Fukui MB, Meltzer CC, Burns R, Kondziolka D, Bozik ME. Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramidate for ependymal or leptomeningeal gliomatosis. *Cancer* 86 (7); 1999: 1347-1353.
- Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK. Outcome and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. *J Clin Oncol* 17; 1999: 2572-2578.
- Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. *J Clin Oncol* 6; 1988: 338.

- Woodle ES. Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway. *J Immunol* 158; 1997: 2156-2164.
- Wright SC. Activation of CPP32 like proteases is not sufficient to trigger apoptosis: inhibition of apoptosis by agents that suppress activation of AP24, but not CPP32-like activity. *J Exp Med* 186; 1997: 1107-1117.
- Wyllie AH, Kerr JF, Currie AR. Cell death: the significance of apoptosis. *Int Rev Cytol* 68; 1980: 251-300.
- Xue L, Fletcher GC, Tolkovsky AM. Autophagy is activated by apoptotic signalling in sympathetic neurons: an alternative mechanism of death execution. *Mol Cell Neurosci* 14; 1999: 180-198.
- Yamamoto S, Sawada K, Simomura H, Kawamura K, James TN. On the nature of cell death during remodeling of hypertrophied human myocardium. *J Mol Cell Cardiol* 32; 2000: 161-175.
- Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome C from mitochondria blocked. *Science* 275; 1997: 1129-1132.
- Yao Y, Kubota T, Sato K, Kitai R, Takeuchi H, Arishima H. Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumors. *Acta Neurochir (Wien)* 143; 2001: 159-166.
- Yoshida H. *Cell* 94 (6); 1998: 739.
- Yoshii Y, Saito A, Hyodo A, Tsurushima H, Sun L. Expression of enzymes and oncogene induced after radiotherapy and/or chemotherapy in patients with brain tumors. *Hum Cell* 14 (1); 2001: 95-103.
- Young B, Oldfield EH, Markesbery WR. Reoperation for glioblastoma. *J Neurosurg* 55; 1981: 917.
- Yung WA, Horton BC, Shapiro WR. Meningeal gliomatosis: A review of 12 cases. *Ann Neurol* 8; 1980: 605.
- Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. *J Clin Oncol* 17 (9); 1999a: 2762-2771.
- Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. *J Clin Oncol* 17 (9); 1999b: 2762-2771.
- Yung WK, Tepper SJ, Young DF. Diffuse bone marrow metastasis by glioblastoma: premortem diagnosis by peroxidase-antiperoxidase staining for glial fibrillary acidic protein. *Ann Neurol* 14 (5); 1983: 581-585.
- Zaidi AU, McDonough JS, Klocke BJ, Latham CB, Kormeyer SJ, Flavell RA, Schmidt RE, Roth KA. Chloroquine induced neuronal cell death is p53 and Bcl-2 family dependent but caspase independent. *J Neuropathol Exp Neurol* 60; 2001: 937-945.
- Zakeri Z, Bursch W, Tenniswood M, Lockshin RA. Cell death: programmed apoptosis, necrosis, or other? *Cell death and differentiation* 2; 1995: 83-92.

- Zakeri Z, Lockshin RA. Cell death during development. *J Immunol Methods* 265; 2002: 3-20.
- Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez-Monterrey I, Castedo M, Kroemer G. Mitochondrial control of nuclear apoptosis. *J Exp Med* 183; 1996: 1533-1544.
- Zeng H. Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor induced endothelium migration and proliferation, respectively. *J Biol Chem* 276; 2001: 32714-32719.
- Zimmermann M, Preac-Mursic V. In vitro activity of taurolidine, chlorophenol-camphor-menthol and chlorhexidine against oral pathogenic microorganisms. *Arzneimittelforschung* 42 (9); 1992: 1157-1159.
- Zimmermann RA. Imaging of adult central nervous system primary malignant gliomas. Staging and follow up. *Cancer* 67; 1991: 1278.
- Zou H. *Cell* 90 (3); 1997: 405.
- Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to *C. elegans* CED-4, participates in cytochrome c-dependent activation of caspase-3. *Cell* 90; 1997: 405-413.
- Zülch KJ (1979). Histologic typing of tumor of the central nervous system. International histological classification of tumors, no. 21. Geneva, World Health Organization.